Amer M Zeidan

41PUBLICATIONS
215CO-AUTHORS
Haematological tumoursRegenerative medicine (incl. stem cells)Gene and molecular therapyMedical mycologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (41)

|Aug 31, 2026
Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study.

|Aug 27, 2026
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

|Jun 29, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

|Apr 30, 2026
How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?

|Apr 25, 2026
Acute myeloid leukemia after myeloproliferative neoplasms: Real-world outcomes in the new treatment era in the United States.

|Apr 14, 2026
A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions.

Jan Philipp Bewersdorf, Alain Mina, Maximilian Stahl

Pageof 7

Frequent Collaborators

10 joint publications

Jan Phillip Bewersdorf

8 joint publications

Rami S Komrokji

7 joint publications

Valeria Santini

6 joint publications

Maria Diez-Campelo